The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The U.S. FDA has approved the expanded use of Organon's TOFIDENCE, a biosimilar to Roche's Actemra, to treat life-threatening immune reactions. The new indications include Cytokine Release Syndrome (CRS) in cancer patients and hospitalized COVID-19 patients, including pediatric cases, who require breathing support. These approvals, issued between June 10 and June 13, allow the drug to be used for a broader range of critical care and inflammatory conditions.